GlassScriptPhysician profile
Mara Grosswald
NPI 1538312558
$7,379.92
in general payments reported to CMS, 2019-2025
23 companies · $1,933 in 2025
The $1,933 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $919 · 2022: $1,350 · 2023: $1,508 · 2024: $1,670 · 2025: $1,933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,946 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,946.41 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,552.80 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $989.24 | 2021-2025 | Dupixent |
| Janssen Biotech, INC. | $914.62 | 2022-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $871.38 | 2023-2025 | |
| Galderma Laboratories, L.P. | $558.50 | 2021-2025 | Nemluvio, Dysport |
| E.R. Squibb & Sons, L.L.C. | $401.04 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $291.74 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $270.16 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Lilly USA, LLC | $209.28 | 2022-2025 | Ebglyss, Olumiant, Taltz |
| Pfizer INC. | $193.28 | 2021-2025 | |
| Incyte Corporation | $160.05 | 2022-2023 | Opzelura |
| Mayne Pharma Commercial LLC | $159.29 | 2021-2025 | |
| Journey Medical Corporation | $135.15 | 2021-2025 | |
| Almirall LLC | $128.50 | 2023-2025 | Seysara, Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $126.59 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $102.83 | 2021-2022 | |
| Organon LLC | $85.75 | 2024-2025 | Vtama |
| Ucb, INC. | $77.82 | 2021-2025 | Bimzelx |
| Botanix Sb INC | $63.06 | 2025 | Sofdra |
| Leo Pharma INC. | $40.35 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $18.11 | 2024 | Ycanth |
| Fresenius Kabi USA, LLC | $16.31 | 2023 | Idacio |
| Dermavant Sciences, INC. | $14.07 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mara Grosswald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.